Anti-TIF1 gamma/TRIM33 Antibody Picoband™ (monoclonal, 8I8)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IF, ICC, FC |
---|---|
Primary Accession | Q9UPN9 |
Host | Mouse |
Isotype | Mouse IgG2b |
Reactivity | Human |
Clonality | Monoclonal |
Format | Lyophilized |
Description | Anti-TIF1 gamma/TRIM33 Antibody Picoband™ (monoclonal, 8I8) . Tested in Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Human. |
Reconstitution | Add 0.2ml of distilled water will yield a concentration of 500ug/ml. |
Gene ID | 51592 |
---|---|
Other Names | E3 ubiquitin-protein ligase TRIM33, 2.3.2.27, Ectodermin homolog, RET-fused gene 7 protein, Protein Rfg7, RING-type E3 ubiquitin transferase TRIM33, Transcription intermediary factor 1-gamma, TIF1-gamma, Tripartite motif-containing protein 33, TRIM33, KIAA1113, RFG7, TIF1G |
Calculated MW | 150 kDa |
Application Details | Western blot, 0.1-0.5 µg/ml, Human Immunohistochemistry (Paraffin-embedded Section), 0.5-1 µg/ml, Human Immunocytochemistry/Immunofluorescence, 4 µg/ml, Human Flow Cytometry, 1-3 µg/1x10^6 cells, Human |
Contents | Each vial contains 4mg Trehalose, 0.9mg NaCl, 0.2mg Na2HPO4, 0.01mg NaN3. |
Clone Names | Clone: 8I8 |
Immunogen | E.coli-derived human TIF1 gamma recombinant protein (Position: M1001-K1127). Human TIF1 gamma shares 96.1% amino acid (aa) sequence identity with mouse TIF1 gamma. |
Purification | Immunogen affinity purified. |
Storage | Store at -20˚C for one year from date of receipt. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for six months. Avoid repeated freeze-thaw cycles. |
Name | TRIM33 |
---|---|
Synonyms | KIAA1113, RFG7, TIF1G |
Function | Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:16751102, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/progenitor (By similarity). Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade). |
Cellular Location | Nucleus. Note=In discrete nuclear dots resembling nuclear bodies (By similarity). Localizes to sites of DNA damage (PubMed:25593309). {ECO:0000250|UniProtKB:Q99PP7, ECO:0000269|PubMed:25593309} |
Tissue Location | Expressed in stem cells at the bottom of the crypts of the colon (at protein level). Expressed in colon adenomas and adenocarcinomas (at protein level). Expressed in brain, lung, liver, spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas, small intestine, ovary, colon, skeletal muscle and hematopoietic progenitors |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Tripartite motif-containing 33 (TRIM33), also known as transcriptional intermediary factor 1 gamma (TIF1-γ), is a human gene. The TRIM33 gene is mapped to chromosome 1p13 by FISH. The protein encoded by this gene is thought to be a transcriptional corepressor. However, molecules that interact with this protein have not yet been identified. The protein is a member of the tripartite motif family. This motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. Three alternatively spliced transcript variants for this gene have been described; however, the full-length nature of one variant has not been determined.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.